Mathias W Amrein

Title: Mathias W Amrein: Innovator in Pulmonary Surfactant Dysfunction Treatment

Introduction

Mathias W Amrein is a notable inventor based in Calgary, Canada. He has made significant contributions to the field of pulmonary medicine, particularly in the treatment of pulmonary surfactant dysfunction. His innovative approach focuses on utilizing cholesterol-sequestering agents to mitigate oxidative damage to pulmonary surfactant.

Latest Patents

Mathias W Amrein holds a patent titled "Treatment Of Pulmonary Surfactant Dysfunction Using Cholesterol-Sequestering Cyclodextrins." This patent discloses the use of cholesterol-sequestering agents, such as methyl-beta-cyclodextrin, for treating pulmonary surfactant dysfunction. The research revealed that oxidative damage to pulmonary surfactant occurs due to the interaction between reactive oxygen species and cholesterol. By removing cholesterol from pulmonary surfactant through the addition of a cholesterol-sequestering agent, oxidative damage to the surfactant is effectively mitigated. Furthermore, it was demonstrated that methyl-beta-cyclodextrin can restore normal function to dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non-cystic fibrosis bronchiolitis.

Career Highlights

Mathias W Amrein is currently associated with Solaero Med Inc., where he continues to advance his research and innovations in pulmonary medicine. His work has the potential to significantly improve treatment outcomes for patients suffering from pulmonary surfactant dysfunction.

Collaborations

Some of his notable coworkers include Lasantha C Gunasekara and Ryan Pratt. Their collaborative efforts contribute to the ongoing research and development in the field.

Conclusion

Mathias W Amrein's innovative work in the treatment of pulmonary surfactant dysfunction showcases his commitment to advancing medical science. His research has the potential to greatly benefit patients with respiratory conditions.